Allen & Overy LLP has advised Grünenthal in connection with the conclusion of Schuldschein loan agreements with a total volume of EUR 300 million. The Schuldschein loan is split into tranches with maturities from three to seven years. The transaction has attracted a number of new investors and allows Grünenthal to broaden its investor base whilst diversifying its funding sources. The transaction marks Grünenthal's debut in the Schuldschein market.

Grünenthal is an independent, family-owned pharmaceutical company headquartered in Aachen. It is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal's products are sold in more than 155 countries. Approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of approx. EUR 1.4 bn.

With its innovative research, the Grünenthal Group is specialised in pain, gout and inflammation. The company's ambition is to become a EUR 2 billion company by 2022 and to deliver four to five new products to patients in diseases with high unmet medical need.

Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. Being strongly committed to innovation, Grünenthal is investing in own research and development above the industrial average.

The Allen & Overy team comprised partner Dr. Neil George Weiand and senior associate Elke Funken-Hötzel (both Banking and Finance, Frankfurt).

Grünenthal was advised in-house by general counsel Marcus Heppner and Sabine Kruth (Director Global Legal).